Vitreous albumin redox state in open-angle glaucoma patients and controls: a pilot study.
Albumin
Free radicals
Glaucoma
Open-angle glaucoma
Vitreous
Journal
International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
24
07
2019
accepted:
30
12
2019
pubmed:
12
1
2020
medline:
11
3
2021
entrez:
12
1
2020
Statut:
ppublish
Résumé
Numerous studies suggest that reactive oxygen species play a crucial role in the development of glaucoma. Since glaucoma patients exhibit posterior vitreous detachment earlier than controls, it has been suggested that reactive oxygen species-increased in glaucoma-also affect the vitreous. In the present study we evaluated the influence of open-angle glaucoma oxidative stress on the redox state of vitreous albumin. Albumin redox states of the vitreous and plasma were evaluated in 22 subjects-11 open-angle glaucoma patients and 11 controls-matched for age, gender, and vitreous state. According to the redox state of cysteine-34, albumin can be separated into: human mercaptalbumin (the thiol form), human nonmercaptalbumin1 (a reversible modification due to mild oxidation), and human nonmercaptalbumin2 (an irreversible modification due to severe oxidation). Albumin of both, the open-angle glaucoma group and the control group, was more oxidized in the vitreous compared to plasma. Furthermore, significantly higher human nonmercaptalbumin1 fractions were found in the vitreous of open-angle glaucoma patients compared to controls. No significant differences were found in the plasma albumin fractions between the groups. Our results support the hypothesis that oxidative stress plays a crucial role in open-angle glaucoma and that reactive oxygen species in glaucomatous eyes may also affect the vitreous.
Identifiants
pubmed: 31925660
doi: 10.1007/s10792-019-01268-5
pii: 10.1007/s10792-019-01268-5
doi:
Substances chimiques
Albumins
0
Reactive Oxygen Species
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
999-1006Références
J Glaucoma. 2007 May;16(3):334-43
pubmed: 17438430
Invest Ophthalmol Vis Sci. 1979 Oct;18(10):1000-18
pubmed: 225285
Prog Retin Eye Res. 2006 Sep;25(5):490-513
pubmed: 16962364
Invest Ophthalmol Vis Sci. 2009 Nov;50(11):5251-8
pubmed: 19516005
PLoS One. 2012;7(11):e49680
pubmed: 23189153
Free Radic Biol Med. 2005 Aug 1;39(3):365-73
pubmed: 15993335
Am J Med. 2003 Jun 1;114(8):638-46
pubmed: 12798451
Biochim Biophys Acta. 2008 Jul-Aug;1782(7-8):469-73
pubmed: 18498776
Acta Ophthalmol. 2011 Mar;89(2):e174-9
pubmed: 20064117
Redox Biol. 2016 Oct;9:100-103
pubmed: 27454767
Surv Ophthalmol. 2010 Mar-Apr;55(2):108-33
pubmed: 20159228
Free Radic Biol Med. 2008 Aug 15;45(4):367-76
pubmed: 18489911
J Pharmacol Exp Ther. 2000 Dec;295(3):1022-30
pubmed: 11082437
Naunyn Schmiedebergs Arch Pharmacol. 2018 Jan;391(1):51-58
pubmed: 29080912
Int J Mol Med. 2016 Oct;38(4):995-1002
pubmed: 27572245
Curr Eye Res. 2011 Aug;36(8):713-8
pubmed: 21780920
Curr Eye Res. 2019 Aug;44(8):856-862
pubmed: 30884982
Br J Pharmacol. 2007 Jul;151(5):580-90
pubmed: 17471184
J Pharmacol Exp Ther. 2013 Mar;344(3):637-45
pubmed: 23249625
Arch Ophthalmol. 2009 Apr;127(4):475-82
pubmed: 19365028
Invest Ophthalmol Vis Sci. 2008 Nov;49(11):4872-80
pubmed: 18971427
Saudi Med J. 2015 Jun;36(6):671-7
pubmed: 25987108
Arch Ophthalmol. 2005 Apr;123(4):458-63
pubmed: 15824217
JAMA. 2014 May 14;311(18):1901-11
pubmed: 24825645
Free Radic Biol Med. 2020 Jan;146:257-263
pubmed: 31705958
Invest Ophthalmol Vis Sci. 1996 Aug;37(9):1849-53
pubmed: 8759353
Exp Eye Res. 2007 Mar;84(3):389-99
pubmed: 17196589
Methods Enzymol. 2010;474:181-95
pubmed: 20609911
PLoS One. 2016 Dec 1;11(12):e0166915
pubmed: 27907028
Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4594-9
pubmed: 16303954
Acta Ophthalmol. 2017 May;95(3):276-280
pubmed: 27966831